Dr. Reddy’s Stock (RDY): Profit Crashed 69% to a 52-Week Low — Overreaction, or Broken Engine?

Dr. Reddy's Laboratories Ltd. (RDY) Q1 FY2027 — Dr. Reddy's (RDY), the ~$9.5B Indian generics-and-specialty pharma, reported Q1 FY2027 (quarter ended June 30) on July 22 — and the NYSE ADR fell ~9.4% to a fresh 52-week low. Net profit collapsed 69% to ₹443 crore (~$46M) and revenue slipped 6% to ₹80.7B (~$837M), missing estimates by nearly half; EBITDA fell 56% and the margin more than halved, from 26.7% to 12.5%. But two very different things caused it: a KNOWN patent cliff — the four-year generic-Revlimid (lenalidomide) window closed in January, sending North America down 35% — and a ONE-TIME ₹240-crore semaglutide API write-off. Strip both out and the base business grew double-digits everywhere else: Emerging Markets +31%, India +17%, Europe +13%, PSAI +4%. Dr. Reddy's runs a net-cash balance sheet (₹3,058 cr surplus, ~$317M) and reaffirmed FY27 guidance. Diluted EPS fell from ₹17.00 to ₹5.30 (~$0.055/ADR). Our owner-earnings DCF centers near $10 vs the ~$11.40 price. Dr. Reddy's Laboratories (RDY) is one of India's largest drugmakers — a ~$9.5B generics-and-specialty pharma in Hyderabad, run by G V Prasad and CEO Erez Israeli, that sells complex generics mostly into the U.S. On July 22 it reported a Q1 FY2027 that looked catastrophic: net profit down 69% to ₹443 crore, revenue down 6% to ₹80.7B, EBITDA down 56%, diluted EPS from ₹17.00 to ₹5.30 — and the ADR fell ~9% to a 52-week low. But the collapse was mostly two one-off items. First, a KNOWN cliff: a four-year limited-competition license to sell generic Revlimid (lenalidomide) — a high-margin windfall — expired in January, driving North America down 35% to ₹2,205 crore. Second, a genuine ONE-TIME stumble: a ₹240-crore write-off of an out-of-spec semaglutide API batch (supply expected back by late Oct/early Nov). Strip both out and the underlying base grew double-digits in every other region — Emerging Markets +31%, India +17%, Europe +13% — and the adjusted EBITDA margin was 15.4%. The balance sheet is net cash (₹3,058 cr surplus), R&D runs ~7% of sales, and management reaffirmed FY27 guidance. The bull case: over-punished for a known cliff plus a one-timer. The bear case: the U.S. profit windfall is structurally gone, the semaglutide slip flags execution risk on the very pivot (peptides/biosimilars) meant to replace it, and on normalized earnings the stock isn't cheap. Our owner-earnings DCF (base ~$420M FCF, +5%/+10% paths, 8.5–11.5% discount for EM + FX risk, ADD net cash, ~834M shares) centers near $10 vs ~$11.40 — the ~9% drop closed the gap but left no margin of safety. Our call: HOLD, 3/5. We're MORE CAUTIOUS than the Street (lean Buy, ~$14.5 ADR target, ~+27% — but those targets predate the miss). We'd buy under ~$9, or on proof the refill is working. Not financial advice. THE CALL: HOLD (3/5, A NET-CASH PHARMA IN A SELF-INFLICTED TROUGH — A KNOWN LENALIDOMIDE CLIFF PLUS A ONE-TIME SEMAGLUTIDE STUMBLE, BUT WITH THE U.S. WINDFALL GONE AND THE REFILL UNPROVEN, THE ~9% DROP LEFT NO MARGIN OF SAFETY) — base-case value ~$10 vs ~$11.40 today. KEY METRICS: - Revenue ₹80.7B (~$837M), −6% YoY — missed ~₹88B estimate - Net profit ₹443 cr (~$46M), −69% YoY — missed ~₹818 cr estimate by nearly half - Diluted EPS ₹5.30 (~$0.055/ADR), down from ₹17.00 - EBITDA ₹1,009 cr, −56%; margin 12.5% (was 26.7%); 15.4% ex the one-time charge - Gross margin 46.5% (49.4% ex-charge); total expenses +13.6% as sales fell - North America −35% to ₹2,205 cr (lenalidomide/gRevlimid window closed Jan 2026) - Base business double-digit: Emerging Mkts +31%, India +17%, Europe +13%, PSAI +4% - One-time ₹240 cr semaglutide API write-off; supply back ~late Oct/early Nov - Net cash surplus ₹3,058 cr (~$317M) at Jun 30; R&D ~7% of sales; FY26 dividend ₹8/sh - FY27 guidance reaffirmed (sales + profit); ADR 1:1; FX ~₹96.4/USD; ~834M shares - Our owner-earnings DCF fair value ~$10 vs ~$11.40 — HOLD 3/5, no margin of safety - Street lean Buy (6B/4H/2S), ~$14.5 ADR target — but predates the miss; likely trimmed What to watch: evidence the refill is replacing the lost U.S. windfall — the semaglutide relaunch landing on schedule (late Oct/early Nov), biosimilar approvals like abatacept, and India + emerging-market growth holding double-digits into a cleaner FY28 — would justify an upgrade; the risks to respect are U.S. price erosion outrunning the base, another quality stumble, or the pipeline slipping, so watch the base-business growth rate and the semaglutide restart every quarter Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.